MedTrace Logo

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

NCT02760316 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-10-17

No results posted yet for this study

Summary

A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD9567.

Conditions

Interventions

DRUG

AZD9567 10 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 20 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 40 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 80 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

Prednisolone 20 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 125 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 155 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

Prednisolone 5 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

Prednisolone 40 mg

Oral Multiple doses 5 days of treatment Once daily

Sponsors & Collaborators

Principal Investigators

  • Rainard Fuhr, Dr. med. · PAREXEL Early Phase Clinical Unit, Berlin

  • Pablo ForteSoto, Dr. · PAREXEL Early Phase Clinical Unit, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-02
Primary Completion
2017-09-11
Completion
2017-09-11

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02760316 on ClinicalTrials.gov